Apil Drug Patent Portfolio
Apil owns 9 orange book drugs protected by 29 US patents with Femcon Fe having the least patent protection, holding only 1 patent. And Actonel with maximum patent protection, holding 16 patents. Given below is the list of Apil's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7704984 | Extended estrogen dosing contraceptive regimen | 02 Feb, 2029 | Active |
| US7645459 | Dosage forms of bisphosphonates | 09 Jan, 2028 | Active |
| US7645460 | Dosage forms of risedronate | 09 Jan, 2028 | Active |
| US8246989 | Dosage forms of bisphosphonates | 16 Jan, 2026 | Active |
| US7572779 | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation | 02 Oct, 2025 | Active |
| US7192938 | Method of treatment using bisphosphonic acid | 06 Nov, 2023 | Expired |
| US7718634 | Method of treatment using bisphosphonic acid | 06 Nov, 2023 | Expired |
| US7192938 | Method of treatment using bisphosphonic acid | 06 May, 2023 | Expired |
| US7718634 | Method of treatment using bisphosphonic acid | 06 May, 2023 | Expired |
| US6962908 | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation | 21 Dec, 2021 | Expired |
| US7799771 | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation | 21 Dec, 2021 | Expired |
| US6652880 | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants | 29 Mar, 2020 | Expired |
| US6667050 | Chewable oral contraceptive | 06 Apr, 2019 | Expired |
| US6465443 | Method for inhibiting bone resorption | 14 Feb, 2019 | Expired |
| US5994329 | Method for inhibiting bone resorption | 17 Jan, 2019 | Expired |
| US6015801 | Method for inhibiting bone resorption | 17 Jan, 2019 | Expired |
| US6432932 | Method for inhibiting bone resorption | 17 Jan, 2019 | Expired |
| US6165513 | Film-coated tablet for improved upper gastrointestinal tract safety | 10 Dec, 2018 | Expired |
| US6465443 | Method for inhibiting bone resorption | 14 Aug, 2018 | Expired |
| US5994329 | Method for inhibiting bone resorption | 17 Jul, 2018 | Expired |
| US6015801 | Method for inhibiting bone resorption | 17 Jul, 2018 | Expired |
| US6432932 | Method for inhibiting bone resorption | 17 Jul, 2018 | Expired |
| US6165513 | Film-coated tablet for improved upper gastrointestinal tract safety | 10 Jun, 2018 | Expired |
| US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy | 22 Jul, 2014 | Expired |
| US5583122 | Pharmaceutical compositions containing geminal diphosphonates | 10 Jun, 2014 | Expired |
| US5622721 | Dosage forms of risedronate | 21 Apr, 2014 | Expired |
| US5583122 | Pharmaceutical compositions containing geminal diphosphonates | 10 Dec, 2013 | Expired |
| US5541170 | Orally administrable pharmaceutical compositions | 30 Jul, 2013 | Expired |
| US5541171 | Orally administrable pharmaceutical composition | 30 Jul, 2013 | Expired |
Latest Legal Activities on Apil's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Apil.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jan, 2024 | US8246989 (Litigated) |
|
Expire Patent
Critical
| 24 Oct, 2022 | US7799771 |
|
Maintenance Fee Reminder Mailed
Critical
| 10 May, 2022 | US7799771 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Sep, 2021 | US7704984 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Sep, 2021 | US7704984 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Jul, 2021 | US7645459 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Jul, 2021 | US7645460 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Feb, 2021 | US7572779 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Feb, 2020 | US8246989 (Litigated) |
|
Expire Patent
Critical
| 22 Apr, 2019 | US7192938 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 05 Nov, 2018 | US7192938 (Litigated) |
|
Expire Patent
Critical
| 18 Jun, 2018 | US7718634 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Mar, 2018 | US7799771 |
| Post Issue Communication - Certificate of Correction | 24 Jan, 2018 | US7799771 |
|
Maintenance Fee Reminder Mailed
Critical
| 01 Jan, 2018 | US7718634 (Litigated) |
Apil's Drug Patent Litigations
Apil's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 03, 2015, against patent number US7704984. The petitioner Mylan Pharmaceuticals Inc., challenged the validity of this patent, with Warner Chilcott Company, LLC as the respondent. Click below to track the latest information on how companies are challenging Apil's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7704984 | February, 2015 |
Terminated-Denied
(20 Aug, 2015)
| Warner Chilcott Company, LLC | Mylan Pharmaceuticals Inc. |
Apil Drug Patents' Oppositions Filed in EPO
Apil drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 29, 2008, by Ratiopharm Gmbh. This opposition was filed on patent number EP03722591A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP07014362A | Jun, 2018 | ALIUD PHARMA GmbH / STADA Arzneimittel GmbH | Revoked |
| EP07014362A | Oct, 2015 | Gedeon Richter Plc. | Revoked |
| EP07014362A | Oct, 2015 | Hexal AG | Revoked |
| EP07014362A | Oct, 2015 | Actavis Group PTC EHF | Revoked |
| EP07014362A | Oct, 2015 | Generica Ilac Sanayi ve Ticaret A.S. | Revoked |
| EP07014362A | Jun, 2015 | Agrobiogen GmbH Biotechnologie | Revoked |
| EP07014362A | Feb, 2015 | Laboratorios Liconsa, S.A. | Revoked |
| EP07014362A | Jan, 2015 | G. L. Pharma GmbH | Revoked |
| EP07014362A | Jan, 2015 | Avansor Pharma Oy | Revoked |
| EP07014362A | Jan, 2015 | Glenmark Pharmaceuticals s.r.o. | Revoked |
| EP07014362A | Jan, 2015 | Stada-Arzneimittel Aktiengesellschaft | Revoked |
| EP07014362A | Jan, 2015 | Synthon BV | Revoked |
| EP05735411A | Mar, 2011 | APOTEX INC. | Revoked |
| EP03722591A | Feb, 2011 | Sandoz Farmacêutica, Lda. | Revoked |
| EP03722591A | Jul, 2008 | Gedeon Richter Plc. | Revoked |
| EP03722591A | Jul, 2008 | PLIVA HRVATSKA d.o.o. | Revoked |
| EP03722591A | Jul, 2008 | Generics [UK] Limited | Revoked |
| EP03722591A | Jul, 2008 | Synthon BV | Revoked |
| EP03722591A | Jul, 2008 | Teva Pharmaceutical Industries Ltd. et al. | Revoked |
| EP03722591A | Jul, 2008 | ALFRED, E. TIEFENBACHER GMBH & CO. KG | Revoked |
| EP03722591A | Jul, 2008 | Laboratorios Liconsa, S.A. | Revoked |
| EP03722591A | May, 2008 | Ratiopharm GmbH | Revoked |
Apil's Family Patents
Apil Drug List
Given below is the complete list of Apil's drugs and the patents protecting them.
1. Actonel
Actonel is protected by 16 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7192938
(Pediatric)
| Method of treatment using bisphosphonic acid |
06 Nov, 2023
(11 months ago)
| Expired |
| US7718634
(Pediatric)
| Method of treatment using bisphosphonic acid |
06 Nov, 2023
(11 months ago)
| Expired |
| US7192938 | Method of treatment using bisphosphonic acid |
06 May, 2023
(1 year, 5 months ago)
| Expired |
| US7718634 | Method of treatment using bisphosphonic acid |
06 May, 2023
(1 year, 5 months ago)
| Expired |
| US6465443
(Pediatric)
| Method for inhibiting bone resorption |
14 Feb, 2019
(5 years ago)
| Expired |
| US5994329
(Pediatric)
| Method for inhibiting bone resorption |
17 Jan, 2019
(5 years ago)
| Expired |
| US6015801
(Pediatric)
| Method for inhibiting bone resorption |
17 Jan, 2019
(5 years ago)
| Expired |
| US6432932
(Pediatric)
| Method for inhibiting bone resorption |
17 Jan, 2019
(5 years ago)
| Expired |
| US6165513
(Pediatric)
| Film-coated tablet for improved upper gastrointestinal tract safety |
10 Dec, 2018
(5 years ago)
| Expired |
| US6465443 | Method for inhibiting bone resorption |
14 Aug, 2018
(6 years ago)
| Expired |
| US5994329 | Method for inhibiting bone resorption |
17 Jul, 2018
(6 years ago)
| Expired |
| US6015801 | Method for inhibiting bone resorption |
17 Jul, 2018
(6 years ago)
| Expired |
| US6432932 | Method for inhibiting bone resorption |
17 Jul, 2018
(6 years ago)
| Expired |
| US6165513 | Film-coated tablet for improved upper gastrointestinal tract safety |
10 Jun, 2018
(6 years ago)
| Expired |
| US5583122
(Pediatric)
| Pharmaceutical compositions containing geminal diphosphonates |
10 Jun, 2014
(10 years ago)
| Expired |
| US5583122 | Pharmaceutical compositions containing geminal diphosphonates |
10 Dec, 2013
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Actonel's drug page
2. Asacol
Asacol is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5541170 | Orally administrable pharmaceutical compositions |
30 Jul, 2013
(11 years ago)
| Expired |
| US5541171 | Orally administrable pharmaceutical composition |
30 Jul, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Asacol's drug page
3. Atelvia
Atelvia is protected by 6 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7645459 | Dosage forms of bisphosphonates |
09 Jan, 2028
(3 years from now)
| Active |
| US7645460 | Dosage forms of risedronate |
09 Jan, 2028
(3 years from now)
| Active |
| US8246989 | Dosage forms of bisphosphonates |
16 Jan, 2026
(1 year, 2 months from now)
| Active |
| US5583122
(Pediatric)
| Pharmaceutical compositions containing geminal diphosphonates |
10 Jun, 2014
(10 years ago)
| Expired |
| US5622721 | Dosage forms of risedronate |
21 Apr, 2014
(10 years ago)
| Expired |
| US5583122 | Pharmaceutical compositions containing geminal diphosphonates |
10 Dec, 2013
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Atelvia's drug page
4. Femcon Fe
Femcon Fe is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6667050 | Chewable oral contraceptive |
06 Apr, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Femcon Fe's drug page
5. Femtrace
Femtrace is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7572779 | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
02 Oct, 2025
(11 months from now)
| Active |
| US6962908 | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
21 Dec, 2021
(2 years ago)
| Expired |
| US7799771 | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
21 Dec, 2021
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Femtrace's drug page
Explore Our Curated Drug Screens
6. Lo Loestrin Fe
Lo Loestrin Fe is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7704984 | Extended estrogen dosing contraceptive regimen |
02 Feb, 2029
(4 years from now)
| Active |
| US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
22 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lo Loestrin Fe's drug page
7. Lo Minastrin Fe
Lo Minastrin Fe is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7704984 | Extended estrogen dosing contraceptive regimen |
02 Feb, 2029
(4 years from now)
| Active |
| US6667050 | Chewable oral contraceptive |
06 Apr, 2019
(5 years ago)
| Expired |
| US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
22 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lo Minastrin Fe's drug page
8. Minastrin 24 Fe
Minastrin 24 Fe is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6667050 | Chewable oral contraceptive |
06 Apr, 2019
(5 years ago)
| Expired |
| US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
22 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Minastrin 24 Fe's drug page
9. Taytulla
Taytulla is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6652880 | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
29 Mar, 2020
(4 years ago)
| Expired |
| US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
22 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Taytulla's drug page